LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.



Monitoring is just as important as getting treatment

Certain side effects of LEMTRADA can happen months and even years after treatment. That's why it is important to begin monitoring after your first infusion, and continue regular monitoring until 4 years or longer after your last treatment course.

LEMTRADA patient discusses required monitoring
“ The monthly monitoring is
very important.

I am glad that they're watching out for me.

– Jennifer

What Nurse Lynne says

MS One to One is a support service to help LEMTRADA patients on their relapsing multiple sclerosis treatment journey

Care Partners: You can talk to an MS One to One® Nurse about LEMTRADA and MS at any time.* Just call

*As a member of MS One to One, you'll have access to an on-duty Nurse 24/7. Regular MS One to One call center hours are Mon—Fri, 8:30 am—8:00 pm ET.

Some of the serious side effects can include autoimmune diseases, which may cause death. These may include blood, thyroid, and kidney disorders (e.g., anti-glomerular basement membrane disease). Kidney disease can lead to kidney failure needing dialysis or transplant and can be life-threatening if untreated. LEMTRADA may also be associated with some kinds of cancers, including skin cancer (melanoma), thyroid cancer, and blood cancers (e.g., lymphoproliferative disorders and lymphoma).

Because of risks of autoimmunity, infusion reactions, and some kinds of cancers, LEMTRADA is only available through a restricted program called the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program.

During an appointment, your healthcare provider will tell you more about the program and how to enroll.

In addition to the REMS program, there are other steps taken to keep track of certain LEMTRADA side effects, like monitoring.

Monitoring may help your healthcare provider find side effects early.

Monitoring includes:

Monitoring includes:

  • Monthly blood and urine lab tests
  • Ongoing symptom self‑checks
  • Yearly skin checks

It is important to have your urine and blood tested, even if you are feeling well and do not have any symptoms from LEMTRADA or MS.

You have lab monitoring options

If you choose LEMTRADA, you will have a range of free-of-charge options for monthly blood and urine testing. Whether you choose to be tested at home, work, or at your doctor's office, we offer an option for you. Talk to your healthcare provider about which option works best for you.

The following lab monitoring options are covered by the LEMTRADA Central Lab Program at no cost to you:

  • LabCorp® or Quest Diagnostics®
    patient service centers
  • Lab tech visits in the comfort
    of your home or office
  • Your healthcare
    provider’s office

Trademarks not owned by Genzyme Corporation or Sanofi are the property of their respective owners.

If the samples are taken at your healthcare provider’s office, you may have to pay a co-pay cost. However, the cost of analyzing the samples will be covered by the LEMTRADA Central Lab Program.

We’re here for you

Our personalized patient support program, MS One to One®, will be there to help at every step of your treatment journey. Our team of nurses can help you understand side effects, remind you of your monitoring schedule, and find testing site options.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit or call 1‑800‑FDA‑1088 1‑800‑FDA‑1088.